The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Lung Cancer Molecular Diagnostics Market Research Report 2025
Synopsis
A molecular approach for diagnosing lung cancer
The global Lung Cancer Molecular Diagnostics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Lung Cancer Molecular Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Lung Cancer Molecular Diagnostics.
Report Scope
The Lung Cancer Molecular Diagnostics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Lung Cancer Molecular Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Lung Cancer Molecular Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Foundationmedicine
Roche
Qiagen
Liferiver
Tellgen
Genetech
Gpmedical
Sansure
Amoydx
Mole
Annoroad
Segment by Type
PCR
FISH
DNA Sequencing
Gene Chip
Segment by Application
Clinical Diagnosis
Drug Screening
Research
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Lung Cancer Molecular Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
A molecular approach for diagnosing lung cancer
The global Lung Cancer Molecular Diagnostics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Lung Cancer Molecular Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Lung Cancer Molecular Diagnostics.
Report Scope
The Lung Cancer Molecular Diagnostics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Lung Cancer Molecular Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Lung Cancer Molecular Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Foundationmedicine
Roche
Qiagen
Liferiver
Tellgen
Genetech
Gpmedical
Sansure
Amoydx
Mole
Annoroad
Segment by Type
PCR
FISH
DNA Sequencing
Gene Chip
Segment by Application
Clinical Diagnosis
Drug Screening
Research
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Lung Cancer Molecular Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Lung Cancer Molecular Diagnostics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 PCR
1.2.3 FISH
1.2.4 DNA Sequencing
1.2.5 Gene Chip
1.3 Market by Application
1.3.1 Global Lung Cancer Molecular Diagnostics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Clinical Diagnosis
1.3.3 Drug Screening
1.3.4 Research
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Lung Cancer Molecular Diagnostics Market Perspective (2019-2030)
2.2 Lung Cancer Molecular Diagnostics Growth Trends by Region
2.2.1 Global Lung Cancer Molecular Diagnostics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Lung Cancer Molecular Diagnostics Historic Market Size by Region (2019-2024)
2.2.3 Lung Cancer Molecular Diagnostics Forecasted Market Size by Region (2025-2030)
2.3 Lung Cancer Molecular Diagnostics Market Dynamics
2.3.1 Lung Cancer Molecular Diagnostics Industry Trends
2.3.2 Lung Cancer Molecular Diagnostics Market Drivers
2.3.3 Lung Cancer Molecular Diagnostics Market Challenges
2.3.4 Lung Cancer Molecular Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Lung Cancer Molecular Diagnostics Players by Revenue
3.1.1 Global Top Lung Cancer Molecular Diagnostics Players by Revenue (2019-2024)
3.1.2 Global Lung Cancer Molecular Diagnostics Revenue Market Share by Players (2019-2024)
3.2 Global Lung Cancer Molecular Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Lung Cancer Molecular Diagnostics Revenue
3.4 Global Lung Cancer Molecular Diagnostics Market Concentration Ratio
3.4.1 Global Lung Cancer Molecular Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Lung Cancer Molecular Diagnostics Revenue in 2023
3.5 Lung Cancer Molecular Diagnostics Key Players Head office and Area Served
3.6 Key Players Lung Cancer Molecular Diagnostics Product Solution and Service
3.7 Date of Enter into Lung Cancer Molecular Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Lung Cancer Molecular Diagnostics Breakdown Data by Type
4.1 Global Lung Cancer Molecular Diagnostics Historic Market Size by Type (2019-2024)
4.2 Global Lung Cancer Molecular Diagnostics Forecasted Market Size by Type (2025-2030)
5 Lung Cancer Molecular Diagnostics Breakdown Data by Application
5.1 Global Lung Cancer Molecular Diagnostics Historic Market Size by Application (2019-2024)
5.2 Global Lung Cancer Molecular Diagnostics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Lung Cancer Molecular Diagnostics Market Size (2019-2030)
6.2 North America Lung Cancer Molecular Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Lung Cancer Molecular Diagnostics Market Size by Country (2019-2024)
6.4 North America Lung Cancer Molecular Diagnostics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Lung Cancer Molecular Diagnostics Market Size (2019-2030)
7.2 Europe Lung Cancer Molecular Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Lung Cancer Molecular Diagnostics Market Size by Country (2019-2024)
7.4 Europe Lung Cancer Molecular Diagnostics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Lung Cancer Molecular Diagnostics Market Size (2019-2030)
8.2 Asia-Pacific Lung Cancer Molecular Diagnostics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Lung Cancer Molecular Diagnostics Market Size by Region (2019-2024)
8.4 Asia-Pacific Lung Cancer Molecular Diagnostics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Lung Cancer Molecular Diagnostics Market Size (2019-2030)
9.2 Latin America Lung Cancer Molecular Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Lung Cancer Molecular Diagnostics Market Size by Country (2019-2024)
9.4 Latin America Lung Cancer Molecular Diagnostics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Lung Cancer Molecular Diagnostics Market Size (2019-2030)
10.2 Middle East & Africa Lung Cancer Molecular Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Lung Cancer Molecular Diagnostics Market Size by Country (2019-2024)
10.4 Middle East & Africa Lung Cancer Molecular Diagnostics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Foundationmedicine
11.1.1 Foundationmedicine Company Detail
11.1.2 Foundationmedicine Business Overview
11.1.3 Foundationmedicine Lung Cancer Molecular Diagnostics Introduction
11.1.4 Foundationmedicine Revenue in Lung Cancer Molecular Diagnostics Business (2019-2024)
11.1.5 Foundationmedicine Recent Development
11.2 Roche
11.2.1 Roche Company Detail
11.2.2 Roche Business Overview
11.2.3 Roche Lung Cancer Molecular Diagnostics Introduction
11.2.4 Roche Revenue in Lung Cancer Molecular Diagnostics Business (2019-2024)
11.2.5 Roche Recent Development
11.3 Qiagen
11.3.1 Qiagen Company Detail
11.3.2 Qiagen Business Overview
11.3.3 Qiagen Lung Cancer Molecular Diagnostics Introduction
11.3.4 Qiagen Revenue in Lung Cancer Molecular Diagnostics Business (2019-2024)
11.3.5 Qiagen Recent Development
11.4 Liferiver
11.4.1 Liferiver Company Detail
11.4.2 Liferiver Business Overview
11.4.3 Liferiver Lung Cancer Molecular Diagnostics Introduction
11.4.4 Liferiver Revenue in Lung Cancer Molecular Diagnostics Business (2019-2024)
11.4.5 Liferiver Recent Development
11.5 Tellgen
11.5.1 Tellgen Company Detail
11.5.2 Tellgen Business Overview
11.5.3 Tellgen Lung Cancer Molecular Diagnostics Introduction
11.5.4 Tellgen Revenue in Lung Cancer Molecular Diagnostics Business (2019-2024)
11.5.5 Tellgen Recent Development
11.6 Genetech
11.6.1 Genetech Company Detail
11.6.2 Genetech Business Overview
11.6.3 Genetech Lung Cancer Molecular Diagnostics Introduction
11.6.4 Genetech Revenue in Lung Cancer Molecular Diagnostics Business (2019-2024)
11.6.5 Genetech Recent Development
11.7 Gpmedical
11.7.1 Gpmedical Company Detail
11.7.2 Gpmedical Business Overview
11.7.3 Gpmedical Lung Cancer Molecular Diagnostics Introduction
11.7.4 Gpmedical Revenue in Lung Cancer Molecular Diagnostics Business (2019-2024)
11.7.5 Gpmedical Recent Development
11.8 Sansure
11.8.1 Sansure Company Detail
11.8.2 Sansure Business Overview
11.8.3 Sansure Lung Cancer Molecular Diagnostics Introduction
11.8.4 Sansure Revenue in Lung Cancer Molecular Diagnostics Business (2019-2024)
11.8.5 Sansure Recent Development
11.9 Amoydx
11.9.1 Amoydx Company Detail
11.9.2 Amoydx Business Overview
11.9.3 Amoydx Lung Cancer Molecular Diagnostics Introduction
11.9.4 Amoydx Revenue in Lung Cancer Molecular Diagnostics Business (2019-2024)
11.9.5 Amoydx Recent Development
11.10 Mole
11.10.1 Mole Company Detail
11.10.2 Mole Business Overview
11.10.3 Mole Lung Cancer Molecular Diagnostics Introduction
11.10.4 Mole Revenue in Lung Cancer Molecular Diagnostics Business (2019-2024)
11.10.5 Mole Recent Development
11.11 Annoroad
11.11.1 Annoroad Company Detail
11.11.2 Annoroad Business Overview
11.11.3 Annoroad Lung Cancer Molecular Diagnostics Introduction
11.11.4 Annoroad Revenue in Lung Cancer Molecular Diagnostics Business (2019-2024)
11.11.5 Annoroad Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
